Vaccines against Autoimmune Diseases Recently, several new avenues have been explored in development of therapeutics against autoimmune diseases and in particular, Multiple Sclerosis. MS is a debilitating disease that affects individuals, primarily women, in their peak and most productive years. There is no known cure for MS, which seems to encompass a spectrum of neurodegenerative processes that affect the brain and spinal cord. Several disease-modifying therapies are being used that target some aspect of the inflammatory process of MS and could reduce the severity of relapses. Some examples are Copaxone, Betaseron, Lemtrafa, Tysabri, Tecfidera, Rebif, Gilenya, Extavia, Avonex and Aubagio. The cost of these therapies range from $20,000-$40,000 per year. In view of increasing costs associated with drugs that varying effects on patients, new therapies against MS are warranted. An interesting approach that seems to use cellular therapy is now gaining ground and consists of us
Posts
Showing posts from May, 2015